AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.
作者信息
Ko Cynthia W, Singh Siddharth, Feuerstein Joseph D, Falck-Ytter Corinna, Falck-Ytter Yngve, Cross Raymond K
机构信息
Division of Gastroenterology, University of Washington, Seattle, Washington.
Division of Gastroenterology, University of California, San Diego, La Jolla, California.
出版信息
Gastroenterology. 2019 Feb;156(3):748-764. doi: 10.1053/j.gastro.2018.12.009. Epub 2018 Dec 18.
Abstract
摘要
相似文献
1
AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.美国胃肠病学会关于轻至中度溃疡性结肠炎管理的临床实践指南。
Gastroenterology. 2019 Feb;156(3):748-764. doi: 10.1053/j.gastro.2018.12.009. Epub 2018 Dec 18.
2
Mild-to-Moderate Ulcerative Colitis Guideline.轻度至中度溃疡性结肠炎指南。
Gastroenterology. 2019 Feb;156(3):768. doi: 10.1053/j.gastro.2019.01.037. Epub 2019 Jan 23.
3
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.AGA 技术评论：轻度至中度溃疡性结肠炎的治疗。
Gastroenterology. 2019 Feb;156(3):769-808.e29. doi: 10.1053/j.gastro.2018.12.008. Epub 2018 Dec 18.
4
Mild-to-Moderate Ulcerative Colitis (UC) Clinical Decision Support Tool.轻至中度溃疡性结肠炎（UC）临床决策支持工具
Gastroenterology. 2019 Feb;156(3):765. doi: 10.1053/j.gastro.2019.01.038. Epub 2019 Jan 23.
5
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.布地奈德多重基质制剂治疗美沙拉嗪抵抗的轻中度溃疡性结肠炎的疗效：一项随机、安慰剂对照试验。
J Crohns Colitis. 2017 Jul 1;11(7):785-791. doi: 10.1093/ecco-jcc/jjx032.
6
Mesalamine with MMX technology for the treatment of ulcerative colitis.采用MMX技术的美沙拉嗪用于治疗溃疡性结肠炎。
Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):299-314. doi: 10.1586/17474124.2.3.299.
7
Mesalamine in the treatment and maintenance of remission of ulcerative colitis.美沙拉嗪治疗和维持溃疡性结肠炎缓解。
Expert Rev Clin Pharmacol. 2012 Mar;5(2):113-23. doi: 10.1586/ecp.12.2.
8
ACG Clinical Guideline: Ulcerative Colitis in Adults.ACG 临床指南：成人溃疡性结肠炎。
Am J Gastroenterol. 2019 Mar;114(3):384-413. doi: 10.14309/ajg.0000000000000152.
9
Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.延长释放型美沙拉秦治疗急性轻至中度溃疡性结肠炎的疗效
Inflamm Bowel Dis. 2009 Jan;15(1):1-8. doi: 10.1002/ibd.20580.
10
Editorial: mesalazine in ulcerative colitis--is it time to revise treatment guidelines in the UK?社论：美沙拉嗪治疗溃疡性结肠炎——英国是否该修订治疗指南了？
Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:1. doi: 10.1111/j.1365-2036.2006.03068.x.
引用本文的文献
1
Prospective Questionnaire Survey on Adherence to Oral 5-Aminosalicylic Acid in Patients With Ulcerative Colitis.溃疡性结肠炎患者口服5-氨基水杨酸依从性的前瞻性问卷调查
JGH Open. 2025 Aug 21;9(8):e70259. doi: 10.1002/jgh3.70259. eCollection 2025 Aug.
2
Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review.美国食品药品监督管理局（FDA）与欧洲药品管理局（EMA）关于溃疡性结肠炎药物研发指南的比较：专家小组综述
J Crohns Colitis. 2025 Jul 3;19(7). doi: 10.1093/ecco-jcc/jjaf111.
3
Optimizing 5-Aminosalicylic Acid Maintenance Treatment in Ulcerative Colitis from the Patient and Physician Perspective: A Cross-sectional Multicenter Study.从患者和医生角度优化溃疡性结肠炎的5-氨基水杨酸维持治疗：一项横断面多中心研究
Crohns Colitis 360. 2025 May 30;7(3):otaf038. doi: 10.1093/crocol/otaf038. eCollection 2025 Jul.
4
Exploring the interconnection between PANoptosis and chronic inflammatory diseases: identifying key targets and therapeutic strategies for periodontitis and ulcerative colitis.探索PANoptosis与慢性炎症性疾病之间的相互联系：确定牙周炎和溃疡性结肠炎的关键靶点及治疗策略。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 2. doi: 10.1007/s00210-025-04320-7.
5
Bile acid receptors regulate the role of intestinal macrophages in inflammatory bowel disease.胆汁酸受体调节肠道巨噬细胞在炎症性肠病中的作用。
Front Immunol. 2025 Jun 17;16:1577000. doi: 10.3389/fimmu.2025.1577000. eCollection 2025.
6
Prolonged time to treatment of biologics in inflammatory bowel disease: disparities from a retrospective study in a tertiary referral centre in the UK.炎症性肠病中生物制剂治疗延迟：来自英国一家三级转诊中心回顾性研究的差异
BMC Gastroenterol. 2025 May 9;25(1):352. doi: 10.1186/s12876-025-03909-9.
7
Expressed Emotions in Patients with Mild to Moderate Ulcerative Colitis: A Descriptive Study.轻至中度溃疡性结肠炎患者的表达性情绪：一项描述性研究。
Ann Neurosci. 2025 Apr 30:09727531251330071. doi: 10.1177/09727531251330071.
8
Oral exacerbates ulcerative colitis via the oral-gut axis: mechanisms and therapeutic implications.口腔通过口肠轴加重溃疡性结肠炎：机制及治疗意义
Front Cell Infect Microbiol. 2025 Apr 7;15:1564169. doi: 10.3389/fcimb.2025.1564169. eCollection 2025.
9
Probiotics: a promising future in the treatment of ulcerative colitis?益生菌：在溃疡性结肠炎治疗中前景可期？
Pharmacol Rep. 2025 Jun;77(3):645-657. doi: 10.1007/s43440-025-00724-7. Epub 2025 Apr 11.
10
Precision microbiota therapy for IBD: premise and promise.用于炎症性肠病的精准微生物群疗法：前提与前景。
Gut Microbes. 2025 Dec;17(1):2489067. doi: 10.1080/19490976.2025.2489067. Epub 2025 Apr 7.
本文引用的文献
1
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.AGA 技术评论：轻度至中度溃疡性结肠炎的治疗。
Gastroenterology. 2019 Feb;156(3):769-808.e29. doi: 10.1053/j.gastro.2018.12.008. Epub 2018 Dec 18.
2
Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.基于人群队列的成人溃疡性结肠炎自然史：系统评价。
Clin Gastroenterol Hepatol. 2018 Mar;16(3):343-356.e3. doi: 10.1016/j.cgh.2017.06.016. Epub 2017 Jun 16.
3
Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis.系统评价与荟萃分析：粪便微生物群移植诱导活动性溃疡性结肠炎缓解的研究
Aliment Pharmacol Ther. 2017 Aug;46(3):213-224. doi: 10.1111/apt.14173. Epub 2017 Jun 14.
4
Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial.低剂量口服姜黄素对轻至中度溃疡性结肠炎的缓解诱导无效：一项随机双盲安慰剂对照试验的结果。
World J Gastrointest Pharmacol Ther. 2017 May 6;8(2):147-154. doi: 10.4292/wjgpt.v8.i2.147.
5
2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial.2.4克美沙拉嗪（艾迪莎400毫克片剂）每日一次在维持溃疡性结肠炎缓解方面与每日三次同样有效：一项随机、非劣效性、多中心试验
Inflamm Bowel Dis. 2017 May;23(5):822-832. doi: 10.1097/MIB.0000000000001065.
6
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.布地奈德多重基质制剂治疗美沙拉嗪抵抗的轻中度溃疡性结肠炎的疗效：一项随机、安慰剂对照试验。
J Crohns Colitis. 2017 Jul 1;11(7):785-791. doi: 10.1093/ecco-jcc/jjx032.
7
Adherence in ulcerative colitis: an overview.溃疡性结肠炎的依从性：概述
Patient Prefer Adherence. 2017 Feb 22;11:297-303. doi: 10.2147/PPA.S127039. eCollection 2017.
8
Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.多供体强化粪菌移植治疗活动期溃疡性结肠炎：一项随机安慰剂对照试验。
Lancet. 2017 Mar 25;389(10075):1218-1228. doi: 10.1016/S0140-6736(17)30182-4. Epub 2017 Feb 15.
9
European consensus conference on faecal microbiota transplantation in clinical practice.临床实践中粪便微生物群移植欧洲共识会议
Gut. 2017 Apr;66(4):569-580. doi: 10.1136/gutjnl-2016-313017. Epub 2017 Jan 13.
10
Patient preferences for inflammatory bowel disease treatment objectives.炎症性肠病治疗目标的患者偏好
Dig Liver Dis. 2017 Feb;49(2):152-156. doi: 10.1016/j.dld.2016.09.009. Epub 2016 Sep 21.
Zotero 插件